Clinical Study

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive C

Posted Date: May 15, 2019

  • Investigator: Trisha Wise-Draper
  • Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is an antibody that affects your immune system by


To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer


Go29527, Cancer, Resected Nsclc, Lung

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.